Plus Therapeutics (NASDAQ:PSTV) Trading Up 1.8%

Shares of Plus Therapeutics, Inc. (NASDAQ:PSTV) were up 1.8% on Monday . The company traded as high as $1.75 and last traded at $1.66. Approximately 199,170 shares changed hands during trading, an increase of 523% from the average daily volume of 31,949 shares. The stock had previously closed at $1.63.

Plus Therapeutics Price Performance

The firm has a market cap of $7.10 million, a PE ratio of -0.05 and a beta of 0.59. The business has a fifty day moving average price of $1.86 and a two-hundred day moving average price of $1.79.

Plus Therapeutics (NASDAQ:PSTV) last released its quarterly earnings data on Tuesday, March 5th. The company reported ($0.70) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.78) by $0.08. The firm had revenue of $1.31 million during the quarter, compared to analysts’ expectations of $1.26 million. Plus Therapeutics had a negative return on equity of 805.57% and a negative net margin of 271.04%. As a group, sell-side analysts forecast that Plus Therapeutics, Inc. will post -0.99 EPS for the current fiscal year.

About Plus Therapeutics

Plus Therapeutics, Inc, a clinical-stage pharmaceutical company, focuses on the development, manufacture, and commercialization of treatments for patients with cancer. Its lead drug candidate is Rhenium-186Re obisbemeda, a patented radiotherapy that targets central nervous system cancers and other cancers, including recurrent glioblastoma, leptomeningeal metastases, and pediatric brain cancers.